SREBF2 and breast carcinoma: We verified this pathway in breast cancer cells by treating them with 50 nM rapamycin, a mTORC1 inhibitor, and found that the mRNA and protein levels of SREBP2 were decreased by rapamycin in BT-549 and MDA-MB-231 cells (Fig. 6A).